Pro News Exclusive

What to know about looming FDA decision on first gene-editing therapy

The deadline approaches for the FDA to make a call on the first gene therapy that modifies the stem cells of people with severe sickle cell disease, after U.K. regulators approved the drug, called Casgevy, made by Vertex and CRISPR Therapeutics. Fill out the form to read the full article.

What to know about looming FDA decision on first gene-editing therapy

Fill out the form to read the full article.

Copy link
Powered by Social Snap